BioSpace News Archive

Consequent upon tremendous expansion of gamma detection probe technology for the surgical management of numerous malignancies, the use of gamma probe device continues to rise.

Nordic Nanovector ASA announces that it has completed enrolment into the LYMRIT 37-05 Phase 1 clinical trial of Betalutin® in patients with relapsed/refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.

TearClear, an emerging ophthalmic pharmaceutical company, announced successful completion of pre-IND meeting with the U.S. Food and Drug Administration regarding the development plan for the preservative free multi-dose delivery of a proprietary Latanoprost formulation, including the clinical study design for the registration study.

Internationally Recognized Brain Specialist Brings 35 Years of Clinical Development, Biopharma Entrepreneurship and Military Medical Leadership

--Sierra Chief Development Officer Barbara Klencke to be joined by renowned myelofibrosis experts Jean-Jacques Kiladjian , Ruben Mesa and Srdan Verstovsek--

Ionis Pharmaceuticals, Inc. announced that it will host a live investor day webcast on Monday, December 7th at 11:00 a.m. Eastern Time to provide an overview of its commercial strategy, key opportunities in its cardiovascular and neurological franchises and recent technology advances.

- Trial will evaluate one-time, direct-to-CNS treatment for MPS I - Second novel gene therapy for neurodegenerative disease program to be actively enrolling patients

LianBio, a biotechnology company focused on bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the Company’s Clinical Trial Application (CTA) to conduct the Phase 2a trial of infigratinib in patients with locally advanced or metastatic gastr

Casma Therapeutics, Inc. and Vipergen ApS announced today the signing of a drug discovery agreement. Under the terms of the agreement, Vipergen will apply its proprietary high-fidelity DNA-encoded library (DEL) technology platform to discover novel small-molecule drug leads against a broad range of undisclosed Casma discovery targets

Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of engineered viral immunotherapies, today announced enrollment of the first patients in a Phase 1/2a clinical trial (RAPTOR) of its RIVAL-01/TAK-605 candidate in patients with solid tumors, conducted in collaboration with Takeda Pharmaceutical Company Limited (“Takeda”).